We have a pipeline of novel, first-in-class or best-in-class therapies for the treatment of metabolic and endocrine disorders
| Program | Target | Preclinical | Phase 1 | Phase 2 | Phase 3 | Status |
|---|---|---|---|---|---|---|
| Development Programs | ||||||
| VK2735 Subcutaneous (Dual GLP-1/GIP agonist) | Obesity | Phase 3 in process; | ||||
| VK2735 Oral (Dual GLP-1/GIP agonist) | Obesity | Phase 2a complete | ||||
| Amylin agonist | Obesity | IND Planned 1Q26 | ||||
| Additional Metabolic | ||||||
| VK2809 (TRβ Agonist) | MASH | Phase 2b VOYAGE trial successfully completed | ||||
| VK0214 (TRβ Agonist) | X-ALD | Phase 1b study demonstrated PoC | ||||
| Development Programs | |||
| Preclinical | Phase 1 | Phase 2 | Phase 3 |
| VK2735 Subcutaneous (Dual GLP-1/GIP agonist) - Obesity | |||
| VK2735 Oral (Dual GLP-1/GIP agonist) - Obesity | |||
| Amylin agonist - Obesity | |||
| Additional Metabolic | |||
| Preclinical | Phase 1 | Phase 2 | Phase 3 |
| VK2809 (TRβ Agonist) - MASH | |||
| VK0214 (TRβ Agonist) - X-ALD | |||
Viking’s research and development activities leverage its expertise in metabolism to develop innovative therapeutics designed to improve patients’ lives.
Viking’s clinical programs include VK2735, a novel dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors for the potential treatment of various metabolic disorders. Data from a Phase 1 and a Phase 2 trial evaluating VK2735 (dosed subcutaneously) for metabolic disorders demonstrated an encouraging safety and tolerability profile as well as positive signs of clinical benefit.
Concurrently, the company is evaluating an oral formulation of VK2735 in a Phase 2 trial. Viking is also developing VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders. The compound successfully achieved both the primary and secondary endpoints in a recently completed Phase 2b study for the treatment of biopsy-confirmed non-alcoholic steatohepatitis (NASH) and fibrosis. In a Phase 2a trial for the treatment of non-alcoholic fatty liver disease (NAFLD) and elevated LDL-C, patients who received VK2809 demonstrated statistically significant reductions in LDL-C and liver fat content compared with patients who received placebo.
The company’s newest program is evaluating a series of internally developed dual amylin and calcitonin receptor agonists (or DACRAs) for the treatment of obesity and other metabolic disorders.
In the rare disease space, Viking is developing VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the potential treatment of X-linked adrenoleukodystrophy (X-ALD). In a Phase 1b clinical trial in patients with the adrenomyeloneuropathy (AMN) form of X-ALD, VK0214 was shown to be safe and well-tolerated, while driving significant reductions in plasma levels of very long-chain fatty acids (VLCFAs) and other lipids, as compared to placebo.
